For US Residents
Get the help you need. It only takes a few minutes to get started.
See all thatNovartis Patient Supportcan offer:
Ongoing Support Program
Get personalized support from your Novartis Patient Support Team.
$0 Co-Pay Plus* offer
Privately insured? Pay as little as $0 with your Co-Pay Plus offer for KISQALI and/or FEMARA.
Free Trial Offer
This one-time offer is activated and ready-to-use. It’s available to anyone with a valid prescription regardless of insurance.
If you’d like to sign up on the phone, call 1-866-433-8000, Monday-Friday 8:00 AM-8:00 PM ET (excluding holidays).
*

Limitations apply.

Valid only for those with private insurance. The Program includes the Co-Pay Plus offer, Plus Card (if applicable), and Rebate, with a combined annual limit up to $15,000. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. For purchases of FEMARA only, this offer is NOT valid for Massachusetts patients and is only valid for California patients that meet additional eligibility criteria. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

No purchase required.

This free trial is not health insurance. Void where prohibited by law. Product dispensed pursuant to terms and conditions of offer. Valid only in the US and Puerto Rico. For Massachusetts residents, offer is valid for one of the following: the KISQALI FEMARA Co-Pack or KISQALI and/or generic letrozole. Claims shall not be submitted to any public or private third-party payer or any federal or state health care program for reimbursement. Offer not valid if reproduced or submitted to any other payer. It is illegal for any person to sell, purchase or trade, or offer to sell, purchase or trade, or to counterfeit, this offer. Prescriber ID# is required on prescription. This is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend offer without notice.

IMPORTANT SAFETY INFORMATION

KISQALI may cause serious side effects, including:

Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your health care provider right away if you have any new or worsening symptoms, including:

  • trouble breathing or shortness of breath
  • cough with or without mucus
  • chest pain

Severe skin reactions. Tell your health care provider or get medical help right away if you get severe rash or rash that keeps getting worse; reddened skin; flu-like symptoms; skin pain or burning, blistering of the lips, eyes, or mouth, blisters on the skin or skin peeling, with or without fever.

What is KISQALI?

KISQALI® (ribociclib) is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer:

  • in combination with an aromatase inhibitor for stage II and III early breast cancer with a high risk of coming back
  • that has gotten worse or has spread to other parts of the body (advanced or metastatic breast cancer) in combination with:
  • an aromatase inhibitor as the first endocrine-based therapy; or
  • fulvestrant as the first endocrine-based therapy or following disease progression on endocrine therapy

It is not known if KISQALI is safe and effective in children.

Heart rhythm problems (QT prolongation). KISQALI can cause a heart problem known as QT prolongation. This condition can cause an abnormal heartbeat and may lead to death.

  • Your health care provider should check your heart and do blood tests before and during treatment with KISQALI
  • Tell your health care provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint

Liver problems. KISQALI can cause serious liver problems. Your health care provider should do blood tests to check your liver before and during treatment with KISQALI. Tell your health care provider right away if you get any of the following signs and symptoms of liver problems:

  • yellowing of your skin or the whites of your eyes (jaundice)
  • dark or brown (tea-colored) urine
  • feeling very tired
  • loss of appetite
  • pain on the upper right side of your stomach area (abdomen)
  • bleeding or bruising more easily than normal

Low white blood cell counts (neutropenia). Low white blood cell counts are very common during treatment with KISQALI and may result in infections that may be severe. Your health care provider should check your white blood cell counts before and during treatment with KISQALI. Tell your health care provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills.

Your health care provider may tell you to decrease your dose, temporarily stop, or completely stop taking KISQALI if you develop certain serious side effects during treatment with KISQALI.

What should I tell my health care provider before taking KISQALI?

Before you take KISQALI, tell your health care provider if you:

  • have any heart problems, including heart failure, irregular heartbeats, and QT prolongation
  • have ever had a heart attack
  • have a slow heartbeat (bradycardia)
  • have high blood pressure that is not controlled
  • have decreased thyroid gland (hypothyroidism)
  • have problems with the amount of potassium, calcium, phosphorus, or magnesium in your blood
  • have fever, chills, or any other signs or symptoms of infection
  • have liver problems
  • have kidney problems
  • are pregnant, or plan to become pregnant. KISQALI can harm your unborn baby
    • If you are able to become pregnant, your health care provider should do a pregnancy test before you start treatment with KISQALI
    • Females who are able to become pregnant and who take KISQALI should use effective birth control during treatment and for at least 3 weeks after the last dose of KISQALI
    • Talk to your health care provider about birth control methods that may be right for you during this time
    • If you become pregnant or think you are pregnant, tell your health care provider right away
  • are breastfeeding or plan to breastfeed. It is not known if KISQALI passes into your breast milk. Do not breastfeed during treatment with KISQALI and for at least 3 weeks after the last dose of KISQALI

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KISQALI and other medicines may affect each other, causing side effects. Know the medicines you take. Keep a list of them to show your health care provider or pharmacist when you get a new medicine.

What should I avoid while taking KISQALI?

Avoid eating grapefruit and avoid drinking grapefruit juice during treatment with KISQALI since these may increase the amount of KISQALI in your blood.

The most common side effects of KISQALI in people with early breast cancer include:

  • decreased white blood cell counts
  • decreased red blood cell counts
  • abnormal liver function tests
  • infections
  • increased kidney function test
  • decreased platelet counts
  • nausea
  • headache
  • tiredness

The most common side effects of KISQALI in people with advanced or metastatic breast cancer include:

  • decreased white blood cell counts
  • decreased red blood cell counts
  • increased liver function tests
  • infections
  • nausea
  • increased kidney function test
  • tiredness
  • decreased platelet counts
  • diarrhea
  • vomiting
  • headache
  • constipation
  • hair loss
  • cough
  • rash
  • back pain
  • low blood sugar level

KISQALI may cause fertility problems in males, which may affect your ability to father a child. Talk to your health care provider if this is a concern for you.

Tell your health care provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of KISQALI. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see accompanying full Prescribing Information including Patient Information.